Latest News for: alx

Edit

McPike wins special election for Va. House of Delegates

Washington Blade 12 Feb 2026
Gay Alexandria City Council member Kirk McPike emerged as the decisive winner in a Feb ... McPike, a Democrat, received 81.5 percent of the vote in his race against Republican Mason Butler, according to the local publication ALX Now ... 20 ... Rep ... ....
Edit

Statement of Changes in Beneficial Ownership (Form 4) (ALX Oncology Holdings Inc)

Public Technologies 04 Feb 2026
) FORM 4. Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b) ... See Instruction 10 ... Washington, D.C ... OMB Number. 3235-0287 ... 0.5 ... 2 ... ALX ONCOLOGY HOLDINGS INC [ALXO] 5 ... 6 ... 4) ... ALX Oncology Holdings Inc.
Edit

ALX Oncology Announces Pricing of Underwritten Offering (Form 8-K) (ALX Oncology Holdings Inc)

Public Technologies 30 Jan 2026
ALX Oncology Announces Pricing of Underwritten Offering. SOUTH SAN FRANCISCO, Calif., January 30, 2026 (GLOBE NEWSWIRE) - ALX Oncology Holdings Inc. ("ALX Oncology," Nasdaq ... ALX Oncology Holdings Inc.
Edit

New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept

Hastings Tribune 30 Jan 2026
- Exploratory analysis from Phase 1b/2 breast cancer trial reinforces CD47 as a predictive biomarker for response, as previously observed in the ASPEN-06 trial in HER2-positive gastric cancer – ... .
Edit

ALX Oncology Announces Pricing of Underwritten Offering

Hastings Tribune 30 Jan 2026
30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc.
Edit

New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination ...

Nasdaq Globe Newswire 30 Jan 2026
- Exploratory analysis from Phase 1b/2 breast cancer trial reinforces CD47 as a predictive biomarker for response, as previously observed in the ASPEN-06 trial in HER2-positive gastric cancer – ... .
Edit

New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer (Form 8-K) (ALX Oncology Holdings Inc)

Public Technologies 30 Jan 2026
ALX Oncology's Evorpacept in Combination with Ziihera (zanidatamab-hrii) in ... SOUTH SAN FRANCISCO, Calif., January 30, 2026 (GLOBE NEWSWIRE) - ALX Oncology Holdings Inc. ("ALX Oncology," Nasdaq ... About ALX Oncology. ALX Oncology (Nasdaq.
Edit

Supplemental Prospectus (Form 424B5) (ALX Oncology Holdings Inc)

Public Technologies 30 Jan 2026
ALX ONCOLOGY HOLDINGS INC ... We were then incorporated in Delaware on April 1, 2020 under the name ALX Oncology Holdings Inc ... We use ALX Oncology and other marks as trademarks in the United States and other countries ... ALX Oncology Holdings Inc.
Edit

Management Change/Compensation (Form 8-K) (ALX Oncology Holdings Inc)

Public Technologies 21 Jan 2026
) ... Effective January 21, 2026, the Board of Directors (the "Board") of ALX Oncology Holdings Inc ... Attachments Original document Permalink. Disclaimer. ALX Oncology Holdings Inc ... (noodl. 129012060) .
Edit

Initial Registration Statement for Employee Benefit Plan (Form S-8) (ALX Oncology Holdings Inc)

Public Technologies 21 Jan 2026
). As filed with the Securities and Exchange Commission on January 21, 2026. Registration No. 333-. UNITED STATES ... 20549 ... ALX ONCOLOGY HOLDINGS INC ... ALX Oncology Holdings Inc ... ☐ ... ☐ ... ALX Oncology Holdings Inc ... ALX ONCOLOGY HOLDINGS INC ... ALX Oncology Holdings Inc.
Edit

Investor Presentation ALX presentation at JPM 2026 12Jan2026 FINAL (698186) (ALX Oncology Holdings Inc)

Public Technologies 15 Jan 2026
© ALX Oncology Inc ... ALX is Rapidly Advancing Novel Cancer Treatments ... ALX Oncology ... ALX Oncology ... ALX Oncology is Pursuing a Focused Development Plan with Upcoming Catalysts in 2026 ... ALX-sponsored trial Completed trial ... 5 ALX Oncology ... ALX Oncology .
Edit

ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor

Hastings Tribune 08 Jan 2026
- First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician’s choice of chemotherapy in HER2-positive metastatic breast cancer; interim analysis anticipated Q3 2026 – ... .
Edit

ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference

Enid News & Eagle 08 Jan 2026
08, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc.
Edit

ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004

Nasdaq Globe Newswire 08 Jan 2026
- First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician’s choice of chemotherapy in HER2-positive metastatic breast cancer; interim analysis anticipated Q3 2026 – ... .
Edit

'Free Software Awards' Winners Announced: Andy Wingo, Alx Sa, Govdirectory

Slashdot 14 Dec 2025
This week the Free Software Foundation honored Andy Wingo, Alx Sa, and Govdirectory with this year's annual Free Software Awards (given to community members and groups making "significant" contributions to software freedom)..

Article Search

tools
×
×
×
×